Antithrombotic therapy for patients with valvular heart disease

Herz

Volumn 33, Issue 1, 2008, Pages 44-51

  Vahanian, Alec ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Anticoagulation; Antiplatelet therapy; Valve disease; Valve prosthesis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULATION; CARDIOVASCULAR RISK; DRUG ELUTING STENT; EMBOLISM; HEALTH EDUCATION; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MITRAL VALVE STENOSIS; PREGNANCY; PROSTHETIC VALVE THROMBOSIS; REVIEW; SINUS RHYTHM; VALVULAR HEART DISEASE;

FIBRINOLYTIC AGENTS; HEART VALVE DISEASES; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; THROMBOEMBOLISM;

EID: 39449126479     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-008-3079-3     Document Type: Review

References (53)

1. Abernathy WS, Willis PW III. Thromboembolic complications of rheumatic heart disease. Cardiovasc Clin 1973;5:131-75.
2. Acar J, Iung B, Boissel JP, et al. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 1996;94:2107-12.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
4. Barbetseas J, Nagueh SF, Pitsavos C, et al. Differentiating thrombus from pannus formation in obstructed mechanical prosthetic valves: an evaluation of clinical, transthoracic and transesophageal echocardiographic parameters. J Am Coll Cardiol 1998;32:1410-7.
5. Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guide lines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration with the Society of Cardiovascular Anesthesiologists. J Am Coll Cardiol 2006;48:e1-148.
6. Butchart EG, Gohlke-Barwolf C, Antunes MJ, et al., Working Groups on Valvular Heart Disease, Thrombosis, and Cardiac Rehabilitation and Exercise Physiology, European Society of Cardiology. Recommendations for the management of patients after heart valve surgery. Eur Heart J 2005;26:2463-71.
7. Butchart EG, Ionescu A, Payne N, et al. A new scoring system to determine thromboembolic risk after heart valve replacement. Circulation 2003;108:Suppl II:68-74.
8. Butchart EG, Moreno de la Santa P, Rooney SJ, et al. Arterial risk factors and cerebrovascular events following aortic valve replacement. J Heart Valve Dis 1995;4:1-8.
9. Butchart EG, Payne N, Li HH, et al. Better anticoagulation control improves survival after valve replacement. J Thorac Cardiovasc Surg 2002;123:715-23.
10. Cappelleri JC, Fiore LD, Brophy MT, et al. Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart valve replacement: a meta-analysis. Am Heart J 1995;130:547-52.
11. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000;160:191-6.
12. Chesebro J, Fuster V, Elveback LR. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983;51:1537-41.
13. Coulshed N, Epstein EJ, McKendrick CS, et al. Systemic embolism in mitral valve disease. Br Heart J 1970;32:26-34.
14. Dunn AS, Turpie AGG. Perioperative management of patients receiving oral anticoagulants. A systematic review. Arch Intern Med 2003;163:901-8.
15. Dzavik V, Cohen G, Chan KL. Role of transesophageal echocardiography in the diagnosis and management of prosthetic valve thrombosis. J Am Coll Cardiol 1991;18:1829-33.
16. Elkayam U. Valvular heart disease and pregnancy. Part II: Prosthetic valves. J Am Coll Cardiol 2005;46:403-10.
17. Ferreira I, Dos L, Tornos P, et al. Experience with enoxaparin in patients with mechanical heart valves who must with-hold acenocoumarol. Heart 2003;89:527-30.
18. Fitzmaurice DA, Machin SJ, British Society of Haematology Task Force for Haemostasis and Thrombosis. Recommendations for patients undertaking self management of oral anticoagulation. BMJ 2001;323:985-9.
19. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report by the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006;27:1976-2030.
20. Gherli T, Colli A, Fragnito C, et al. Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study. Circulation 2004;110:496-500.
21. Gohlke-Bärwolf C. Anticoagulation in valvar heart disease: new aspects and management during non-cardiac surgery. Heart 2000;84:567-72.
22. Gohlke-Barwolf C, Acar J, Oakley C, et al. Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 1995;16:1320-30.
23. Gueret P, Vignon P, Fournier P, et al. TEE for the diagnosis and management of nonobstructive thrombosis of mechanical mitral valve prosthesis. Circulation 1995;91:103-10.
24. Huth C, Friedl A, Rost A, for the GELIA Study Investigator Group. Intensity of oral anticoagulation after implantation of St. Jude Medical aortic prosthesis: analysis of the GELIA database [GELIA 4]. Eur Heart J 2001;3:Suppl Q:Q33-8.
25. Hylek EM, Regan S, Go AS, et al. Clinical predictors of prolonged delay in return of the International Normalized Ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001;135:393-400.
26. Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003;24:1231-43.
27. Iung B, Cormier B, Dadez E, et al. Small abnormal echos after mitral valve replacement with bileaflet mechanical prostheses: predisposing factors and effect on thromboembolism. J Heart Valve Dis 1993;2:259-66.
28. Laffort P, Roudaut R, Roques X, et al. Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St. Jude Medical prosthesis: a clinical and transesophageal echocardiographic study. J Am Coll Cardiol 2001;35:739-46.
29. Laplace G, Lafitte S, Labeque JN, et al. Clinical significance of early thrombosis after prosthetic mitral valve replacement: a postoperative monocentric study of 680 patients. J Am Coll Cardiol 2004;43:1283-90.
30. Lengyel M, Horstkotte D, Voller H, et al., Working Group Infection, Thrombosis, Embolism and Bleeding of the Society for Heart Valve Disease. Recommendations for the management of prosthetic valve thrombosis. J Heart Valve Dis 2005;14:567-75.
31. Makris M, Watson HG. The management of coumarin-induced over-anticoagulation. Br J Haematol 2001;114:271-80.
32. Massel D, Little SH. Risks and benefits of adding antiplatelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. J Am Coll Cardiol 2001;37:569-78.
33. Meurin P, Tabet JY, Weber H, et al. Low-molecular-weight heparin as a bridging anticoagulant early after mechanical heart valve replacement. Circulation 2006;113:564-9.
34. Montorsi P, De Bernardi F, Muratori M, et al. Role of cinefluoroscopy, transthoracic, and TEE in patients with suspected prosthetic heart valve thrombosis. Am J Cardiol 2000;85:58-64.
35. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet 2006;368:1005-11.
36. Oakley C, Child A, Iung B, et al., Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003;24:761-81.
37. Orford JL, Fasseas P, Melby S, et al. Safety and efficacy of aspirin, clopidogrel and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 2004;147:463-7.
38. Poli D, Antonucci E, Lombardi A, et al. Low rate of bleeding and thrombotic complications of oral anticoagulant therapy independent of age in the real-practice of an anticoagulation clinic. Blood Coagul Fibrinolysis 2003;14:269-75.
39. Pouleur H, Buyse M. Effects of dipyridamole in combination with anticoagulant therapy on survival and thromboembolic events in patients with prosthetic heart valves. A meta-analysis of the randomized trials. J Thorac Cardiovasc Surg 1995;110:463-72.
40. Rahimtoola SJ. Choice of prosthetic heart valve for adult patients. J Am Coll Cardiol 2003;41:893-904.
41. Rizzoli G, Guglielmi C, Toscano G, et al. Reoperations for acute prosthetic thrombosis and pannus: an assessment of rates, relationship and risk. Eur J Cardiothorac Surg 1999;16:74-80.
42. Roudaut R, Lafitte S, Roudaut MF, et al. Fibrinolysis of mechanical prosthetic valve thrombosis: a single-center study of 127 cases. J Am Coll Cardiol 2003;41:653-8.
43. Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease - native and prosthetic. Chest 2004;126:Suppl:457S-82S.
44. Seshadri N, Goldhaber SZ, Elkayam U, et al. The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients. Am Heart J 2005;150:27-34.
45. Shapira Y, Herz I, Vaturi M, et al. Thrombolysis is an effective and safe therapy in stuck bileaflet mitral valves in the absence of high-risk thrombi. J Am Coll Cardiol 2000;35:1874-80.
46. Silber S, Albertsson P, Aviles FF, et al., Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-47.
47. Tong AT, Roudaut R, Ozkan M, et al., Prosthetic Valve Thrombolysis-Role of Transesophageal Echocardiography (PROTEE) Registry Investigators. Transesophageal echocardiography improves risk assessment of thrombolysis of prosthetic valve thrombosis: results of the international PRO-TEE registry. J Am Coll Cardiol 2004;43:77-84.
48. Torn M, Rosendaal FR. Oral anticoagulation in surgical procedures: risks and recommendations. Br J Haematol 2003;123:676-82.
49. Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart valve replacement. N Engl J Med 1993;329:524-9.
50. Vahanian A, Baumgartner H, Bax J, et al., Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: the Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007;28:230-68.
51. Vahanian A, Iung B, Pierard L, et al. Valvular heart diseases. In: Camm J, Luscher T, Serruys P. eds. The ESC textbook of cardiovascular medicine. London: Blackwell, 2006:625-70.
52. Wahl MJ. Dental surgery in anticoagulated patients. Arch Intern Med 1998;158:1610-6.
53. Wood P. An appreciation of mitral stenosis, I: Clinical features. Br Med J 1954;4870:1051-63.